相关实验视频
Updated: May 28, 2025

08:02
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
18.3K
对吸入氧化的反应和肺高血压的非常早产新生儿的死亡率
Michelle Baczynski1, Dany Weisz2, Laura Thomas1
1Department of Paediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada.
JAMA network open
|February 10, 2025
概括
吸入的氧化 (iNO) 改善了非常早产新生儿早期急性肺高血压的结果. 然而,iNO的响应性并不能预测这个脆弱人群中晚期发作的肺高血压的死亡率.
科学领域:
- 新生儿医学 新生儿医学
- 儿童心脏病学 儿童心脏病学
- 呼吸系统生理学 呼吸系统生理学
背景情况:
- 吸入的氧化 (iNO) 用于治疗非常早产新生儿的急性肺高血压,基于观察到的FiO2改善.
- 在这个人群中,iNO反应的临床有效性和预后价值仍未得到充分研究.
研究的目的:
- 为了确定预测急性肺高血压iNO接受非常早产新生儿的预释前死亡率的因素.
- 具体评估iNO响应能力作为死亡率预测指标的作用.
主要方法:
- 在12个加拿大三级NICU (2018-2022) 进行前性观察队列研究.
- 包括非常早产的新生儿 (<32周GA) 患有急性肺高血压,需要iNO和FiO2≥0.50.
- 单独分析早期 (≤72h) 和晚期 (>72h) 发作的肺高血压队列;定义iNO反应为FiO2减少≥0.20.
主要成果:
- 早期发病组 (n=262) 有较高的iNO反应 (71%) 和较低的死亡率 (34%) 与晚期发病组 (n=109;41%的反应,49%的死亡率) 相比.
- 在早期发病时,更大的FiO2降低与iNO与较低的死亡率相关 (aOR为0.74每0.10 FiO2降低).
- 在晚期发病时,只有疾病严重程度 (较低的iNO前FiO2,较高的pH) 预测死亡率,而不是iNO反应 (aOR 0.47).
结论:
- iNO响应与早期急性肺高血压的非常早产新生儿的更好的结果有关.
- 在这个人群中,iNO响应对晚发性肺高血压的预后意义尚不确定.
- 需要进一步研究晚发性肺高血压的独特病理生理学.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
166
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
166
Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K
Respiratory Assessment: Purpose and Indications
1.0K
Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
1.0K
Pulmonary Hypertension: Classification and Pathogenesis
147
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
147
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145

